Enalapril reduces the incidence of diabetes in patients with chronic heart failure: Insight from the studies of left ventricular dysfunction (SOLVD)

Circulation

Volumn 107, Issue 9, 2003, Pages 1291-1296

  Vermes, Emmanuelle ^a   Ducharme, Anique ^a   Bourassa, Martial G ^a   Lessard, Myriam ^a   White, Michel ^a   Tardif, Jean Claude ^a  

^a MONTREAL HEART INSTITUTE   (Canada)

Author keywords

Angiotensin; Diabetes mellitus; Heart failure; Inhibitors

Indexed keywords

ENALAPRIL; GLUCOSE;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE COURSE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; HAZARD ASSESSMENT; HEART LEFT VENTRICLE FAILURE; HIGH RISK POPULATION; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; MULTICENTER STUDY; PREDICTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SURVIVAL;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BLOOD GLUCOSE; CHRONIC DISEASE; DIABETES MELLITUS; ENALAPRIL; FEMALE; HEART FAILURE, CONGESTIVE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIALS; RETROSPECTIVE STUDIES; RISK FACTORS; VENTRICULAR DYSFUNCTION, LEFT;

EID: 0037432313     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000054611.89228.92     Document Type: Article

References (30)

1. The CONSENSUS trial study group. Effect of enalapril on mortality in severe congestive heart failure. N Engl J Med. 1987;316:1429-1435.
2. The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med. 1992;327:685-691.
3. Packer M, Poole-Wilson PA, Armstrong PW, et al. Comparative effects of low doses and high doses of the angiotensin converting enzyme inhibitor lisinopril on morbidity and mortality in chronic heart failure: ATLAS study group. Circulation. 1999;23:2312-2318.
4. Shindler DM, Kostis JB, Yusuf S, et al. Diabetes mellitus, a predictor of morbidity and mortality in the Studies of Left Ventricular Dysfunction (SOLVD) trials and registry. Am J Cardiol. 1996;77:1017-1020.
5. Bourassa MG, Gurné O, Bangdiwala SI, et al. Natural history and patterns of current practice in heart failure. J Am Coll Cardiol. 1993;22(suppl A):14A-19A.
6. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 1991;325:293-302.
7. Lewis EJ, Hunsicker LG, Bain RP, et al. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J. Med. 1993;329:1456-1462.
8. The ACE Inhibitors in Diabetic Nephropathy Trialist Group. Should all patients with type 1 diabetes mellitus and microalbuminuria receive angiotensin-converting enzyme inhibitors? A meta-analysis of individual patient data. Ann Intern Med. 2001;134:370-379.
9. Parving HH, Larsen M, Hommel E, et al. Effect of antihypertensive treatment on blood-retinal barrier permeability to fluorescein in hypertensive type-1 diabetic patients with background retinopathy. Diabetologia. 1989;32:440-444.
10. The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med. 2000;342:145-153.
11. Yusuf S, Gerstein H, Hoogwerf B, et al. Ramipril and the development of diabetes. JAMA. 2001;286:1882-1885.
12. The SOLVD Investigators. Studies of Left Ventricular Dysfunction (SOLVD): rationale, design and methods: two trials that evaluate the effect of enalapril in patients with reduced ejection fraction. Am J Cardiol. 1990;66:315-322.
13. American Diabetes Association. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care. 1997;20:1183-201.
14. Gress TW, Nieto FJ, Shahar E, et al. Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. N Engl J Med. 2000;342:905-912.
15. Jacob S, Rett K, Wicklmayr M, et al. Differential effect of chronic treatment with two beta-blocking agents on insulin sensitivity: the carvedilol-metoprolol study. J Hypertens. 1996;14:489-494.
16. Hansson L, Lindholm LH, Niskanen L, et al. Effects of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet. 1999;353:611-616.
17. Lindholm LH, Ibsen H, Borch-Johnsen K, et al. Risk of new-onset diabetes in the losartan intervention for endpoint reduction in hypertension study. J Hypertens. 2002:20:1879-1886.
18. Paolisso G, De Riu S, Marrazzo G, et al. Insulin resistance and hyperinsulinemia in patients with chronic congestive heart failure. Metabolism. 1991;40:972-977.
19. Sacks DB, Mc Donald JM. The pathogenesis of type II diabetes mellitus: a polygenic disease. Am J Clin Pathol. 1996;105:149-156.
20. Uehara M, Kishikawa H, Isami S, et al. Effect on insulin sensitivity of angiotensin converting enzyme inhibitors with or without a sulphydryl group: bradykinin may improve insulin resistance in dogs and humans. Diabetologia. 1994;37:300-307.
21. Yang HY, Erdös EG, Levin Y. A dipeptidyl cardoxypeptidase that converts angiotensin I and inactivates bradykinin. Biochim Biophys Acta. 1970;214:374-376.
22. Tomiyama H, Kushiro T, Abeta H, et al. Kinins contribute to the improvement of insulin sensitivity during treatment with angiotensin converting enzyme inhibitor. Hypertension. 1994;23:450-455.
23. 2α and indomethacin on the sensitivity of glycolysis and glycogen synthesis to insulin in stripped soleus muscles of the rat. Biochem J. 1985;27:337-340.
24. Fryer LGD, Hajduch E, Rencurel F, et al. Activation of glucose transport by AMP-activated protein kinase via stimulation of nitric oxide synthase. Diabetes. 2000;49:1978-1985.
25. Henriksen EJ, Jacob S, Kinnick TR, et al. ACE inhibition and glucose transport in insulin-resistant muscle: roles of bradykinin and nitric oxide. Am J Physiol. 1999;277:R332-R336.
26. Balon TW, Nadler JL. Evidence that nitric oxide increases glucose transport in skeletal muscle. J Appl Physiol. 1997;82:359-363.
27. Shultz TA, Lewis SB, Westbie DK, et al. Glucose delivery: a modulator of glucose uptake in contracting skeletal muscle. Am J Physiol. 1977;2:E514-E518.
28. Morel Y, Gadient A, Keller U, et al. Insulin sensitivity in obese hypertensive dyslipidemic patients treated with enalapril or atenolol. J Cardiovasc Pharmacol. 1995;26:306-311.
29. Pollare T, Lithell H, Berne C. A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension. N Engl J Med. 1989;321:868-873.
30. Carlsson PO, Berne C, Jansson L. Angiotensin II and the endocrine pancreas: effects on islet blood flow and insulin secretion in rats. Diabetologia. 1998;41:127-133.